Equities analysts predict that MEDNAX Inc (NYSE:MD) will post earnings per share (EPS) of $0.89 for the current quarter, according to Zacks. Seven analysts have issued estimates for MEDNAX’s earnings, with the lowest EPS estimate coming in at $0.82 and the highest estimate coming in at $0.94. MEDNAX posted earnings per share of $0.92 during the same quarter last year, which indicates a negative year over year growth rate of 3.3%. The firm is expected to announce its next quarterly earnings report on Thursday, February 6th.
According to Zacks, analysts expect that MEDNAX will report full year earnings of $3.35 per share for the current financial year, with EPS estimates ranging from $3.29 to $3.41. For the next financial year, analysts expect that the business will post earnings of $3.47 per share, with EPS estimates ranging from $3.20 to $3.55. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for MEDNAX.
MEDNAX (NYSE:MD) last announced its earnings results on Friday, November 1st. The company reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.83 by $0.08. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The company had revenue of $888.70 million during the quarter, compared to the consensus estimate of $876.20 million. During the same period in the previous year, the firm posted $0.94 earnings per share. The company’s revenue was down .9% on a year-over-year basis.
NYSE:MD opened at $25.91 on Monday. The company has a market cap of $2.18 billion, a price-to-earnings ratio of 7.38, a P/E/G ratio of 1.00 and a beta of 0.75. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.93 and a current ratio of 1.93. The stock’s fifty day moving average price is $25.14 and its two-hundred day moving average price is $23.91. MEDNAX has a 52-week low of $19.93 and a 52-week high of $39.96.
In other MEDNAX news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $22.88, for a total value of $114,400.00. Following the sale, the director now directly owns 10,821 shares in the company, valued at $247,584.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.40% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. acquired a new stake in MEDNAX during the 2nd quarter worth approximately $36,000. Benjamin F. Edwards & Company Inc. increased its position in shares of MEDNAX by 56.2% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the company’s stock worth $40,000 after acquiring an additional 638 shares in the last quarter. Parallel Advisors LLC increased its position in shares of MEDNAX by 78.4% during the third quarter. Parallel Advisors LLC now owns 1,993 shares of the company’s stock worth $45,000 after acquiring an additional 876 shares in the last quarter. US Bancorp DE raised its holdings in shares of MEDNAX by 38.5% during the second quarter. US Bancorp DE now owns 5,657 shares of the company’s stock worth $142,000 after acquiring an additional 1,572 shares during the period. Finally, Robeco Institutional Asset Management B.V. acquired a new stake in shares of MEDNAX during the third quarter worth $161,000. 92.81% of the stock is currently owned by institutional investors and hedge funds.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
See Also: G-20
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.